- Home
- DSGN vs CURV Comparison
DSGN vs CURV Comparison
Compare DSGN & CURV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- CURV
- Stock Information
- Founded
- DSGN 2017
- CURV 2001
- Country
- DSGN United States
- CURV United States
- Employees
- DSGN N/A
- CURV N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- CURV Clothing/Shoe/Accessory Stores
- Sector
- DSGN Health Care
- CURV Consumer Discretionary
- Exchange
- DSGN Nasdaq
- CURV Nasdaq
- Market Cap
- DSGN 348.2M
- CURV 402.0M
- IPO Year
- DSGN 2021
- CURV 2021
- Fundamental
- Price
- DSGN $4.91
- CURV $6.05
- Analyst Decision
- DSGN Hold
- CURV Hold
- Analyst Count
- DSGN 3
- CURV 4
- Target Price
- DSGN $7.00
- CURV $4.33
- AVG Volume (30 Days)
- DSGN 126.2K
- CURV 364.3K
- Earning Date
- DSGN 03-18-2025
- CURV 03-27-2025
- Dividend Yield
- DSGN N/A
- CURV N/A
- EPS Growth
- DSGN N/A
- CURV 29.45
- EPS
- DSGN N/A
- CURV 0.14
- Revenue
- DSGN N/A
- CURV $1,121,714,000.00
- Revenue This Year
- DSGN N/A
- CURV N/A
- Revenue Next Year
- DSGN N/A
- CURV $0.18
- P/E Ratio
- DSGN N/A
- CURV $42.69
- Revenue Growth
- DSGN N/A
- CURV N/A
- 52 Week Low
- DSGN $2.45
- CURV $2.18
- 52 Week High
- DSGN $7.77
- CURV $9.14
- Technical
- Relative Strength Index (RSI)
- DSGN 53.37
- CURV 45.82
- Support Level
- DSGN $3.58
- CURV $5.95
- Resistance Level
- DSGN $5.17
- CURV $6.30
- Average True Range (ATR)
- DSGN 0.40
- CURV 0.31
- MACD
- DSGN 0.11
- CURV -0.10
- Stochastic Oscillator
- DSGN 83.65
- CURV 17.31
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America targeting 27 to 42-year-old women. It is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of e-Commerce platform and stores.